Acurx Pharmaceuticals (ACXP) Scheduled to Post Quarterly Earnings on Wednesday

Acurx Pharmaceuticals (NASDAQ:ACXP) is set to post its quarterly earnings results before the market opens on Wednesday, November 13th. Analysts expect Acurx Pharmaceuticals to post earnings of ($0.23) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Acurx Pharmaceuticals (NASDAQ:ACXP) last issued its quarterly earnings results on Friday, August 9th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02. During the same period in the previous year, the company posted ($0.28) EPS. On average, analysts expect Acurx Pharmaceuticals to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Acurx Pharmaceuticals Stock Performance

Shares of Acurx Pharmaceuticals stock opened at $1.85 on Wednesday. Acurx Pharmaceuticals has a 1 year low of $1.52 and a 1 year high of $5.28. The company has a market cap of $30.06 million, a P/E ratio of -1.57 and a beta of -1.73. The stock has a 50-day moving average price of $2.01 and a 200 day moving average price of $2.15.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Acurx Pharmaceuticals in a report on Monday, August 12th.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.